About-cancer/treatment/clinical-trials/disease/melanoma/treatment
Kurapa Clinical Miedzo yeMelanoma
Kliniki miedzo ndeyekutsvagisa zvidzidzo zvinosanganisira vanhu. Aya makiriniki ekuedzwa pane ino rondedzero ndeyekurapa melanoma. Yese miedzo pane irondedzero inotsigirwa neNCI.
Ruzivo rweNCI rwekutanga nezve zviedzo zvemakiriniki zvinotsanangura mhando nezvikamu zvemiyedzo uye maitirwo azvo. Kliniki miedzo inotarisa nzira nyowani dzekudzivirira, kuona, kana kubata chirwere. Iwe ungangoda kufunga nezve kutora chikamu mukutora kiriniki. Taura nachiremba wako kuti akubatsire kusarudza kana imwe yakakunakira iwe.
Miedzo 1-25 ye 260 1 2 3 ... 11 Inotevera>
Targeted Therapy Inotungamirwa neGenetic Kuedza Mukurapa Varwere vane Advanced Refractory Solid Tumors, Lymphomas, kana Multiple Myeloma (Iyo MATCH Kuongorora Trial)
Ichi chikamu II MATCH chidzidzo chekuongorora mashandisirwo ekurapa ayo anotungamirwa nemajini ekuongorora anoshanda muvarwere vane mamota akasimba kana lymphomas akafambira mberi achiteedzera kana imwechete tambo yekurapa yakajairika kana isina kubvumirana nzira yekurapa iripo. Genetic bvunzo inotarisa yakasarudzika magene echisimba (magene) evarwere tumarara maseru. Varwere vane hutachiona husina kujairika (senge shanduko, kukura, kana kuchinjika) vanogona kubatsirwa zvakanyanya kubva pakurapwa uko kunonamira kwavo bundu. Kuziva izvi zvakasarudzika zvekutanga zvinogona kubatsira vanachiremba kuronga zvirinani kurapwa kwevarwere vane yakasimba mamota, lymphomas, kana akawanda myeloma.
Nzvimbo: 1189 nzvimbo
Pembrolizumab Mukurapa Varwere vane Stage III-IV Yakanyanya-Njodzi Melanoma Pamberi uye Mushure mekuvhiya.
Ichi chikamu chechipiri cheyedzo yekuongorora mashandiro anoita pembrolizumab musati uye mushure mekuvhiyiwa pakurapa varwere vane nhanho III-IV ine njodzi-yakakura melanoma. Immunotherapy ine monoclonal antibodies, senge pembrolizumab, inogona kubatsira immune immune kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Kupa pembrolizumab kare uye mushure mekuvhiyiwa kunogona kushanda zvirinani pakurapa melanoma.
Nzvimbo: 709 nzvimbo
Dabrafenib naTrametinib Inoteverwa neIpilimumab naNivolumab kana Ipilimumab neNivolumab Inoteverwa naDabrafenib naTrametinib Mukurapa Varwere vane Stage III-IV BRAFV600 Melanoma
Ichi chisinganzwisisike chikamu chechitatu cheyedzo yekuongorora maitiro ekutanga kurapwa neipilimumab uye nivolumab ichiteverwa nedabrafenib uye trametinib inoshanda uye ichiienzanisa nekutanga kurapwa ne dabrafenib uye trametinib inoteverwa ne ipilimumab uye nivolumab mukurapa varwere vane nhanho III-IV melanoma ine shanduko inozivikanwa se BRAFV600 uye haigone kubviswa nekuvhiya (kusingachinjike). Immunotherapy ine monoclonal antibodies, senge ipilimumab uye nivolumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Dabrafenib uye trametinib inogona kuvhara bundu kukura nekutarisa iyo BRAFV600 geni.
Nzvimbo: 712 nzvimbo
Ipilimumab ine kana isina Nivolumab Mukurapa Varwere neMelanoma Icho Ndicho Chikamu IV kana Chikamu chechitatu uye Hachigone Kubviswa nekuvhiya
Ichi chikamu chechipiri cheyedzo yekuongorora kuti ipilimumab ine kana isina nivolumab inoshanda sei pakurapa varwere vane melanoma inova nhanho IV kana nhanho III uye isingakwanise kubviswa nekuvhiyiwa. Immunotherapy ine monoclonal antibodies, senge ipilimumab uye nivolumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira.
Nzvimbo: 600 nzvimbo
Pembrolizumab Mukurapa Varwere vane Desmoplastic Melanoma Iyo Inogona Kana Kuti Isingakwanise Kubviswa nekuvhiya.
Ichi chirongwa chekuchaira chikamu chechipiri chekuyedza mashandiro anoita pembrolizumab pakurapa varwere vane desmoplastic melanoma (DM) iyo inogona kana isingakwanise kubviswa nekuvhiya (kusingaonekwe). MaMonoclonal antibodies, kunge pembrolizumab, anogona kuvhara chaiwo mapuroteni ayo anogona kusimbisa immune immune uye kudzora bundu kukura.
Nzvimbo: 202 nzvimbo
Bhasiketi Kudzidza kweEentrectinib (RXDX-101) yekurapa kwevarwere vane Solid Tumors Kuchengeta NTRK 1/2/3 (Trk A / B / C), ROS1, kana ALK Gene Rearrangements (Fusions)
Iyi yakavhurika-label, multicenter, yepasi rose Phase 2 tswanda kudzidza kwe entrectinib (RXDX-101) yekurapa kwevarwere vane mamota akasimba anochengeta iyo NTRK1 / 2/3, ROS1, kana ALK gene fusion. Varwere vanozopihwa kumabhasiketi akasiyana siyana zvinoenderana nebundu mhando uye gene kusanganiswa.
Nzvimbo: 26 nzvimbo
Kudzivirirwa uye Kubudirira kwePembrolizumab Kuenzaniswa neiyo Placebo muKachengetedzwa Yakanyanya-njodzi Stage II Melanoma (MK-3475-716 / KEYNOTE-716)
Ichi chikamu chechipiri-chikamu chinoongorora kuchengetedzeka uye kushanda kwepembrolizumab (MK-3475) zvichienzaniswa ne placebo mune vatori vechikamu vane chirwere chakadzoreredza njodzi-yepamusoro Stage II melanoma. Vatori vechikamu muChikamu 1 vanogashira chero pembrolizumab kana placebo mune yakapofumara-bofu dhizaini inosvika gumi nematanhatu macircule. Vatori vechikamu vanogamuchira placebo kana vanomira kurapwa mushure mekugamuchira gumi nematanhatu epembrolizumab muChikamu 1, havawani chirwere chinodzokororwa mukati memwedzi mitanhatu yekupedzisa pembrolizumab muChikamu 1, uye musamise kurapwa ne pembrolizumab yechirwere chekudzokororazve kana kusagadzikana, vanogona kukodzera gamuchira kusvika makumi matatu nemashanu ekuwedzera masekonzi epembrolizumab muChikamu 2 mune yakavhurika-dhizaini dhizaini Yekutanga fungidziro yechidzidzo ichi ndechekuti pembrolizumab inowedzera kupona-kusununguka-kupona (RFS) zvichienzaniswa ne placebo.
Nzvimbo: 25 nzvimbo
Nivolumab ane kana asina Ipilimumab Mukurapa Vechidiki Varwere neRecurrent kana Refractory Solid Tumors kana Sarcomas
Ichi chikamu I / II kuyedza kunoongorora iyo mhedzisiro uye yakanakisa dosi ye nivolumab painopihwa pamwe kana isina ipilimumab kuti vaone mashandiro avanoshanda pakurapa vadiki vadiki vane mamota akasimba kana sarcomas akadzoka (achidzokororazve) kana asinga pindure kurapwa ( zvinopesana). Immunotherapy ine monoclonal antibodies, senge nivolumab uye ipilimumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Izvo hazvisati zvazivikanwa kana nivolumab inoshanda zvirinani iri yega kana iine ipilimumab mukurapa varwere vanodzokororazve kana kusagadzikana yakasimba mamota kana sarcomas.
Nzvimbo: 24 nzvimbo
Iyo Dose Kukwirisa uye Cohort Kuwedzera Kudzidza kweNKTR-214 muKusanganisa neNivolumab uye Mamwe Anopesana -Cancer Therapies muvarwere Vane Sarudza Yakawedzera Solid Tumors (PIVOT-02)
Muchidzidzo chechina-ichi, NKTR-214 ichaitwa pamwe chete nivolumab muChikamu 1, pamwe chete nivolumab ine kana isina dzakasiyana chemotherapies muChikamu 2, uye nivolumab uye ipilimumab muZvikamu 3 & 4. Muchikamu 1, iyo Chikamu. Yakakurudzirwa Phase 2 Dose (RP2D) ye NKTR-214 pamwe chete nivolumab ichagadziriswa. MuChikamu 2, NKTR-214 ine nivolumab paPR2D ichaongororwa seyekutanga-kurapwa uye / kana seyechipiri kana wechitatu mutsetse kurapwa musarudzo varwere vane Melanoma, Renal Cell Carcinoma (RCC), Isiri-Diki Cell Lung Cancer (NSCLC ), Urothelial Carcinoma (UC), metastatic Breast Cancer (mBC) uye Colorectal Cancer (CRC). Uye zvakare, muchikamu chechipiri, iyo RP2D yeNKTR-214 ine nivolumab uye dzakasiyana chemotherapies uye regimens mumasarudzo akasarudzika evarwere veNSCLC anozotemerwa. Muchikamu 3, akati wandei akasiyana maratidziro ehutatu mubatanidzwa we NKTR-214 pamwe nivolumab uye ipilimumab ichaongororwa musarudzo varwere vane RCC, NSCLC, Melanoma, uye UC. Muchikamu chechina, kuchengetedzeka uye kugona kwekubatanidzwa kwetatu kuchaongororwa mberi mukusarudza varwere vane RCC, NSCLC, Melanoma uye UC.
Nzvimbo: 22 nzvimbo
Phase 1 / 1b Kudzidza Kuongorora Kudzivirirwa uye Kugadzikana kweCPI-444 Ndega uye Mukubatana neAtezolizumab muPamberi Cancers
Ichi chikamu che1 / 1b chakavhurika-chitauro, multicenter, dhosi-sarudzo yekuongorora yeCPI-444, yemumuromo mamorekuru madiki anotarisana neadenosine-A2A receptor pane T-lymphocyte uye mamwe maseru e immune system. Uyu muedzo uchadzidza nezve kuchengetedzeka, kushivirira, uye anti-bundu chiitiko cheCPI-444 seyechete mumiririri uye mukubatana neatezolizumab, PD-L1 inhibitor kurwisa mamota akasiyana akasimba. CPI-444 inovhara adenosine kubva pakusunga kune iyo A2A receptor. Adenosine inodzvinyirira iyo inorwisa-bundu chiitiko cheT maseru uye mamwe maseru ekudzivirira.
Nzvimbo: 22 nzvimbo
Chidzidzo chePembrolizumab (MK-3475) muVatambi veVatori vechikamu vane Advanced Solid Tumor kana Lymphoma (MK-3475-051 / KEYNOTE-051)
Ichi chikamu chechikamu-chechipiri che pembrolizumab (MK-3475) muvatori vechikamu vevana vane chero eanotevera marudzi ekenza: - yakakwira melanoma (mwedzi mitanhatu kusvika <makore gumi nemasere ekuberekwa), - yakakwira, yakadzokazve kana yekuratidzira kufa kwakarongwa- ligand 1 (PD-L1) -positive malignant solid tumor kana imwe lymphoma (mwedzi mitanhatu kusvika <18 yemakore ekuberekwa), - yakadzokororwa kana yekutsoropodza yechinyakare Hodgkin lymphoma (rrcHL) (makore matatu kusvika <makore gumi nemasere ekuberekwa), kana - kumberi kudzokerazve kana kukanganisa microsatellite-kusagadzikana-yakakwira (MSI-H) mamota akasimba (mwedzi mitanhatu kusvika <zera ramakore gumi nemasere). Chikamu chekutanga chichawana dosi inoregererwa (MTD) / yakanyanya kupihwa dosi (MAD), simbisa iyo dosi, uye uwane inokurudzirwa Phase 2 dose (RP2D) ye pembrolizumab therapy. Chikamu chechipiri chichaenderera mberi nekuongorora kuchengetedzeka uye kugona pavana RP2D. Pfungwa yekutanga yechidzidzo ichi ndeyekuti intravenous (IV) manejimendi yepembrolizumab kune vana vane yakanyanya melanoma; PD-L1 inofambira mberi, yakadzokororazve kana yekudzora bundu yakasimba kana imwe lymphoma; yemhando yepamusoro, yakadzokororwa kana inodzora bundu yakasimba yeMSI-H; kana rrcHL, zvinokonzeresa Chinangwa Chekupindura Rate (ORR) chakakura kupfuura gumi muzana yeimwe yemhando idzi dzekenza. NaAmendment 8, kunyoreswa kwevatori vechikamu vane mamota akasimba uye yevatori vechikamu vane makore matanhatu kusvika <makore gumi nemaviri nemelanoma yakavharwa. Kunyoreswa kwevatori vechikamu vane makore -12 kusvika ku -18 makore ane melanoma kunoenderera. Kunyoreswa kwevatori vechikamu vane MSI-H mamota akasimba kunoendererawo. kudzoreredza kana kusagadzikana bundu rakasimba reMSI-H; kana rrcHL, zvinokonzeresa Chinangwa Chekupindura Rate (ORR) chakakura kupfuura gumi muzana yeimwe yemhando idzi dzekenza. NaAmendment 8, kunyoreswa kwevatori vechikamu vane mamota akaomarara uye evatori vechikamu vane makore matanhatu kusvika <makore gumi nemaviri nemelanoma yakavharwa. Kunyoreswa kwevatori vechikamu vane makore -12 kusvika ku -18 makore ane melanoma kunoenderera. Kunyoreswa kwevatori vechikamu vane MSI-H mamota akasimba kunoendererawo. kudzoreredza kana kusagadzikana bundu rakasimba reMSI-H; kana rrcHL, zvinokonzeresa Chinangwa Chekupindura Rate (ORR) chakakura kupfuura gumi muzana yeimwe yemhando idzi dzekenza. NaAmendment 8, kunyoreswa kwevatori vechikamu vane mamota akasimba uye yevatori vechikamu vane makore matanhatu kusvika <makore gumi nemaviri nemelanoma yakavharwa. Kunyoreswa kwevatori vechikamu vane makore -12 kusvika ku -18 makore ane melanoma kunoenderera. Kunyoreswa kwevatori vechikamu vane MSI-H mamota akasimba kunoendererawo.
Nzvimbo: 19 nzvimbo
Kudzivirirwa uye Kubudirira kweIMCgp100 Kusiyanisa neIye Investigator Sarudzo muAdvanced Uveal Melanoma
Kuongorora kupona kwese kweHLA-A * 0201 varwere vakura vane hutachiona hwemberi husina kurapwa hwaigamuchira IMCgp100 zvichienzaniswa neInvestigator Sarudzo yedacarbazine, ipilimumab, kana pembrolizumab.
Nzvimbo: 18 nzvimbo
Enapotamab Vedotin (HuMax-AXL-ADC) Kudzivirirwa Kudzidza mune Varwere Vane Solor Tumors
Chinangwa chekuyedza ndechekuona iyo inoregererwa dhosi uye kumisikidza chengetedzo chimiro cheHuMax-AXL-ADC mune yakasangana huwandu hwevarwere vane yakatsanangurwa yakasimba mamota
Nzvimbo: 18 nzvimbo
Chidzidzo cheXmAb®20717 mune Zvidzidzo zvine Sarudzo Dzakasimba Dzakasimba Tumarara
Ichi chidimbu 1, yakawanda dosi, ichikwira dhosi yekuwedzera kudzidza kutsanangura MTD / RD uye regimen yeXmAb20717, kurondedzera kuchengetedzeka uye kushivirira, kuongorora PK uye immunogenicity, uye kutanga kuongorora anti-bundu chiitiko cheXmAb20717 mune zvidzidzo zvakasarudzwa Mberi yakasimba mamota.
Nzvimbo: 15 nzvimbo
Talimogene Laherparepvec uye Pembrolizumab Mukurapa Varwere vane Stage III-IV Melanoma
Ichi chikamu II chekuyedza chinoongorora mashandiro etalimogene laherparepvec uye pembrolizumab inoshanda mukurapa varwere vane danho III-IV melanoma. Biological Therapies, senge talimogene laherparepvec, shandisa zvinhu zvakagadzirwa kubva kuzvinhu zvipenyu zvinogona kukurudzira kana kudzvinyirira immune system nenzira dzakasiyana uye kumisa tumarara maseru kubva mukukura. Immunotherapy ine monoclonal antibodies, senge pembrolizumab, inogona kubatsira immune immune kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Kupa talimogene laherparepvec uye pembrolizumab kunogona kushanda zvirinani pakurapa varwere vane melanoma nekuderedza bundu.
Nzvimbo: 16 nzvimbo
Dabrafenib, Trametinib, uye Navitoclax Mukurapa Varwere vane BRAF Mutant Melanoma kana Solor Tumors Izvo Zviri Metastatic kana Hazvigone Kubviswa nekuvhiya.
Ichi chikamu cheI / II kuyedza kunoongorora mhedzisiro uye yakanakisa dabrafenib, trametinib, uye navitoclax uye kuona mashandiro avanoita mukurapa varwere vane BRAF mutant melanoma kana mamota akasimba akapararira kune dzimwe nhengo dzomuviri kana asingakwanise kubviswa. nekuvhiya. Dabrafenib, trametinib, uye navitoclax zvinogona kumisa kukura kwemarara maseru nekuvharira mamwe ma enzymes anodiwa kuti sero kukura.
Nzvimbo: 24 nzvimbo
Chidzidzo cheAvelumab Mukusangana Neimwe Kenza Immunotherapies Mune Yakanyanya Malignancies (JAVELIN Medley)
Ichi chikamu cheChikamu 1b / 2 chidzidzo chekuvandudza dosi kuongorora kuchengetedzwa, pharmacokinetics, pharmacodynamics, uye yekutanga antitumor chiitiko cheavelumab (MSB0010718C) mukubatana nemamwe makenza maunomotherapies mune varwere vane yemuno yepamusoro kana metastatic solid tumors. Chinangwa chekutanga ndechekuongorora kuchengetedzeka uye zviratidzo zvekutanga zvekubudirira kweakasiyana-siyana avelumab musanganiswa nemamwe ma cancer immunotherapies, kugadzirisa dosing regimens sezvakakodzera, mune mashoma akateedzana ezviratidzo.
Nzvimbo: 12 nzvimbo
Yekutsvagisa Immuno-Therapy Kudzidza Kuongorora Kudzivirirwa, Kushivirira uye Kubudirira kweAnti-LAG-3 Iine uye Pasina Anti-PD-1 Mukurapa KweZvisimba Zvakasimba.
Chinangwa chechidzidzo ndechekuongorora kuchengetedzeka, kushivirira uye kushanda kwemuyedzo wekuyedza BMS-986016 inoitiswa yega uye pamwe chete nivolumab mune varwere vane mamota akasimba akapararira uye / kana asingakwanise kubviswa nekuvhiya. Aya anotevera mamota anowanikwa mune ino ongororo: Isiri-Diki Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma yemusoro nemutsipa, uye melanoma, izvo zvisati zvamboitika kurapwa ne immunotherapy. NSCLC uye melanoma izvo zvakambove zvakarapwa ne immunotherapy.
Nzvimbo: 12 nzvimbo
Kudzivirirwa, Kushivirira uye PK Kudzidza kweDCC-2618 mune Varwere Vane Yakanyanya Malignancies
Ichi chikamu cheChikamu 1, yakavhurika-chitaridzi, yekutanga-mu-munhu (FIH) yedosi-yekuwedzera kudzidza yakagadzirirwa kuongorora kuchengetedzeka, kushivirira, pharmacokinetics (PK), pharmacodynamics (PD) uye yekutanga antitumor chiitiko cheDCC-2618, inotungamirwa nemuromo (PO), mune varwere vakuru vane malignancies epamberi. Chidzidzo ichi chine zvikamu zviviri, chikamu chekuwedzera kwedosi uye chikamu chekuwedzera.
Nzvimbo: 12 nzvimbo
Chidzidzo cheNKTR-214 Yakasanganiswa neNivolumab vs Nivolumab Yoga muVatori vechikamu Neyaimbove Isingarapike Inoperable kana Metastatic Melanoma
Chinangwa chechidzidzo ndeche kuyedza kushanda (kuti mushonga unoshanda zvakadii), chengetedzo, uye kushivirira kwechirwere chekuferefeta chinonzi NKTR-214, kana ichibatanidzwa nivolumab maringe nivolumab yakapihwa yega muvatori vechikamu nekenza yekenza yeganda isina kurapwa. isingakwanise kuvhiya kana kupararira
Nzvimbo: 10 nzvimbo
Chidzidzo cheRelatlimab Plus Nivolumab vs. Nivolumab Ndega muVatori vechikamu NeAdvanced Melanoma
Chinangwa chechidzidzo ichi ndechekuona kana nivolumab yakabatana nere relatlimab inoshanda kupfuura nivolumab pachayo pakurapa isingagadzirisike melanoma kana melanoma yakapararira
Nzvimbo: 13 nzvimbo
Pembrolizumab neIpilimumab Mukurapa Varwere Vapfuura Vakaitirwa Advanced Melanoma
Ichi chikamu chechipiri cheyedzo yekuongorora mashandiro anoita pembrolizumab uye ipilimumab mukurapa varwere vaimbove vakarapwa melanoma yakapararira kune dzimwe nhengo dzomuviri. Immunotherapy ine monoclonal antibodies, senge pembrolizumab uye ipilimumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira.
Nzvimbo: 10 nzvimbo
Clinical Kudzidza kweCMP-001 mukubatanidzwa nePembrolizumab kana seMonotherapy
Ichi chidzidzo chichaitwa muzvikamu zviviri: Chikamu 1 chichaitiswa kuchishandiswa Dose Kukwirisa uye Kuwedzera dhizaini. Chikamu che1 Dose Escalation Phase yechidzidzo ichi chinozoona muyero wakachengeteka uye unotsungirira kuti uongororwe muchikamu chekuwedzera kwechikamu cheDose. Chikamu chechipiri chekudzidza chichaitwa pamwe chete neChikamu 1 Dose Kuwedzera Chikamu uye ichaongorora kuchengetedzeka nekubudirira kweCMP-001 painotungamirwa semonotherapy.
Nzvimbo: 12 nzvimbo
Phase 1b / 2 Kuedzwa kweLenvatinib (E7080) Uyezve Pembrolizumab mune Zvidzidzo zvine Sarudzo Yakasimba Tumarara.
Ichi chakavhurika-chinyorwa Phase 1b / 2 kuyedzwa kwelenvatinib (E7080) pamwe pembrolizumab muvatori vechikamu vane mamota akasimba akasarudzwa. Phase 1b inoona uye inosimbisa iyo inoregererwa dhizeti (MTD) yelenvatinib pamwe chete nemamirigiramu mazana maviri (mg) (intravenous [IV], vhiki nhatu dzese [Q3W]) pembrolizumab muvatori vechikamu vane mamota akasimba akasarudzwa (kureva asiri-madiki maseru mapapu gomarara, renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma yemusoro nemutsipa, kana melanoma). Phase 2 (Kuwedzera) ichaongorora kuchengetedzeka uye kushanda kwemubatanidzwa mumatanho matanhatu paMTD kubva paPase 1b (lenvatinib 20 mg / zuva nemuromo + pembrolizumab 200 mg Q3W, IV).
Nzvimbo: 10 nzvimbo
Kudzidza kweLifileucel (LN-144), Autologous Tumor Inopinza maLymphocyte, Mukurapa kwevarwere vane Metastatic Melanoma
Inotarisirwa, inopindirana multicenter kudzidza kuongorora inotora masero ekurapa (ACT) kuburikidza nekumisikidzwa kweLN-144 (autologous TIL) inoteverwa ne interleukin 2 (IL-2) mushure meiyo nonmyeloablative lymphodepletion (NMA LD) preonditioning regimen.
Nzvimbo: 13 nzvimbo
1 2 3 ... 11 Inotevera>
